Charles Kelly, MD
Neurology · Mt Pleasant, SCNPI 1760402473
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,658 of the $29,883 with a category attached, or 72.5%. 60 manufacturers reported payments, led by Harmony Biosciences LLC at 29.4% of the total. Reporting peaked in 2021 at $8,868 and has fallen 70.4% since, to $2,628 in 2025. Among neurology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,399 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$9K
- AbbVie$2K
- EMD Serono, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- UCB, Inc.$1K
- Jazz Pharmaceuticals Inc.$1K
- plus $13K from 54 others
Across 4 payments — averaging $7931.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$32K
What the payments were for
- Consulting fees$1,2004%
- Speaking & faculty fees$6,78523%
- Food & beverage$21,65872%
- Education$2401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wakix$7,830
- UBRELVY$449
- QULIPTA$345
- Austedo XR$118
- NUPLAZID$115
How this compares
$29,883 in reported general payments places this provider in the 90th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 35 | $182,167 |
| RebifInterferon Beta-1a/Albumin | 13 | $131,707 |
| IngrezzaValbenazine Tosylate | 11 | $96,209 |
| QuliptaAtogepant | 44 | $56,459 |
| Nurtec OdtRimegepant Sulfate | 36 | $49,261 |
| UbrelvyUbrogepant | 39 | $48,846 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 26 | $32,012 |
| Emgality PenGalcanezumab-Gnlm | 30 | $24,506 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $15,660 |
| RytaryCarbidopa/Levodopa | 20 | $12,862 |
| Divalproex Sodium | 24 | $6,159 |
| Memantine Hcl | 201 | $5,499 |
| Carbamazepine | 38 | $5,188 |
| Levetiracetam | 85 | $4,124 |
| Donepezil Hcl | 222 | $3,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $174 | $182,16735 claims |
| EMD Serono, Inc.Rebif | $1,687 | $131,70713 claims |
| AbbVieQulipta, Ubrelvy | $2,339 | $105,30583 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $721 | $96,20911 claims |
| PfizerNurtec Odt | $748 | $49,26136 claims |
| Amneal Pharmaceuticals LLCRytary | $253 | $12,86220 claims |
| Upsher-smith Laboratories LLCTopiramate | $156 | $1,019109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 270 neurology providers in South Carolina.
Other neurology in Mt Pleasant
- Neil PatelMt Pleasant$24K
- John BakerSumter$779K
- Robert CarlileSummerville$428K
- Mary HughesGreenville$404K
- Jose CardenasAiken$216K
- Fredy RevillaGreenville$208K
- Robert AdamsCharleston$204K
- Thomas HughesMt. Pleasant$102K
- Kathleen WoschkolupGreenville$97K
- Sarah BreevoortCharleston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.